Loading...
NPI 1225110497 · Linden, NJ · Clinical Medical Laboratory
Customize your policy alerts
Get alerted when relevant policies change without checking for updates manually.
Monitor payer policy activity
Accu Reference Medical Lab, LLC is a clinical medical laboratory provider located in Linden, New Jersey. This profile covers 390 Medicare and 452 Medicaid CPT/HCPCS procedure codes, with claims volume, average reimbursement, and total revenue by code, benchmarked against other providers billing the same services.
Provider details (source: NPPES NPI Registry)
| Field | Value |
|---|---|
| Entity Type | Organization |
| Organization | Accu Reference Medical Lab, LLC |
| Address | 1901 E Linden Ave |
| City | Linden |
| State | NJ |
| ZIP | 07036 |
| Taxonomy | Clinical Medical Laboratory |
| NPI Enumerated | October 19, 2006 |
Lifetime revenue by payer source (source: CMS Medicare & Medicaid claims data)
| Payer Source | Total Paid |
|---|---|
| Medicaid | $183M |
| Medicare | $21.2M |
Payer mix is strongly Medicaid‑weighted: the entity reports $21.2M in Medicare revenue versus $183M in Medicaid revenue, so Medicaid represents the dominant share of billed revenue and likely drives strategic contracting and operational capacity. This is effectively a Medicaid‑scale operator with a much smaller Medicare footprint.
Revenue concentration in Medicare is material but not extreme: the top three Medicare codes account for 33.2% of this provider’s total Medicare revenue, driven by G0483 ($2.3M, 15.3%), 87798 ($1.5M, 10.3%), and 82306 ($1.1M, 7.6%). Among those, G0483 and 82306 show unusually high national volumes (G0483 ranks #8 of 1063, 99th percentile, labeled an extreme outlier; 82306 ranks #31 of 12453, 100th percentile, labeled an extreme outlier), while 87798 is high but characterized as more typical in its national ranking (#41 of 1319, 97th percentile).
Medicaid revenue is highly concentrated in a few high‑volume services: the top three Medicaid codes make up 46.3% of Medicaid revenue and are dominated by pandemic and toxicology testing — U0003 ($29.6M, 21.4%), G0483 ($22.4M, 16.2%), and G0481 ($12M, 8.7%). Competitively, G0483 and G0481 are state market leaders (each ranks #1 in‑state and are described as extreme outliers), while U0003 ranks #5 in‑state (97th percentile) and is described as notably above typical state volume, indicating market dominance in both COVID molecular testing and definitive drug testing.
The code mix indicates a laboratory business model focused on high‑throughput infectious disease molecular testing and toxicology/definitive drug panels alongside routine clinical panels. Concrete signals include large Medicaid volumes for U0003 (484.8K claims, $29.6M) and G0483 (230.6K claims, $22.4M), plus high Medicare volumes for panel and screening tests such as 80053 (75K claims, $750.3K) and 85025 (78.9K claims, $631K), consistent with a full‑service clinical lab that also operates substantial forensic/toxicology and COVID testing lines.
Competitive standing differs by payer and code: for Medicaid this provider is a dominant, in‑state leader on multiple drug‑testing codes (G0483 #1 of 32, 100th percentile; G0481 #1 of 39, 100th percentile) and a top five performer on high‑throughput COVID testing (U0003 #5 of 127, 97th percentile). For Medicare the provider is an outlier on many routine lab codes (examples include 82306 rank #31 of 12453, 100th percentile; 80053 rank #51 of 26416, 100th percentile), showing national‑level volume that places it far above typical peers for several assays.
Operational scale is substantial when measured by claim counts across both payers: examples include 484.8K Medicaid claims for U0003, 467.4K Medicaid claims for 80307, 296.1K Medicaid claims for 82306, and high Medicare claim volumes such as 78.9K for 85025 and 75K for 80053. These claim volumes support the characterization of a high‑throughput laboratory with significant specimen intake and processing capacity, particularly for infectious disease and drug testing.
The provider’s long tenure (NPI enumerated 2006-10-19, ~20 years ago) plus the current billing footprint suggests an established laboratory operation that expanded or sustained high volumes through pandemic and routine testing lines. Longevity combined with the present concentration in Medicaid testing implies stable contracts or referral relationships with state programs and high‑volume ordering sources.
Statistical standing across many top codes is explicitly extreme or notably elevated: multiple Medicare codes are flagged as "extreme outlier" in national volume (for example G0483 and 82306), and multiple Medicaid codes are labeled as "extreme outlier" or "notably above typical" in‑state (for example G0483, G0481, U0003). These labels indicate the provider’s activity level is materially above typical peers in the same code buckets and should be treated as a defining feature of its competitive profile.
Medicare revenue breakdown by CPT/HCPCS procedure code.
View: Bar Chart1 / 2
The CPT/HCPCS codes generating the most Medicare revenue for this provider.
390 rows
| CPT/HCPCS Code | Description | Claims | Avg Paid | Revenue |
|---|---|---|---|---|
| G0483 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but… | 9,340 | $240 | $2.3M |
| 87798 | The lab analyst performs a test for an infectious agent not specified in another code using an amplified nucleic acid probe technique. Use this code if you know the laboratory technique is amplified… | 44,570 | $30 | $1.5M |
| 82306 | The lab analyst measures the vitamin D level, typically on a serum specimen. This analyte, commonly known as vitamin D, is not really a vitamin, but is an important steroid hormone that is produced… | 38,420 | $30 | $1.1M |
| G0482 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but… | 4,580 | $200 | $893.9K |
| 84443 | The lab analyst performs a test to measure the amount of thyroid–stimulating hormone (TSH), a hormone produced in the pituitary gland that helps regulate thyroid function. The typical specimen is the… | 55,860 | $20 | $893.8K |
| G0481 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but… | 5,770 | $150 | $883.3K |
| 80061 | The lab analyst performs a lipid panel test in which he measures the blood level of cholesterol and fats called triglycerides in the blood. | 58,200 | $10 | $756.6K |
| 80053 | The lab analyst performs a comprehensive metabolic panel, or CMP test in which he measures the blood level of 14 chemicals the code descriptor lists for the panel. | 75,030 | $10 | $750.3K |
| 85025 | A complete blood count (better known as a CBC) is a blood test request by a doctor that provides detailed information about various types of cells in a patient's blood. Usually a pathologist or a… | 78,880 | $10 | $631K |
| 36415 | In this procedure, the provider inserts a needle into a vein to collect a blood sample. | 75,300 | $10 | $602.4K |
Showing 1–10 of 390
How this provider's Medicare billing volume and revenue compare to other providers nationally and within its state, across 390 CPT/HCPCS codes.
View: State1 / 2
Full comparison — all codes billed, vs. state median
390 rows
| CPT/HCPCS Code | Rank | Provider Count | Median Claims | Avg Paid | Average Revenue |
|---|---|---|---|---|---|
| 87506 | 6 | 10 | 110 | $260 | $506.1K |
| 87798 | 2 | 40 | 1,760 | $30 | $284.3K |
| 87536 | 5 | 10 | 2,150 | $80 | $207K |
| 87150 | 4 | 10 | 430 | $30 | $175.3K |
| 86769 | 4 | 20 | 100 | $40 | $140.5K |
| G0483 | 1 | 40 | 60 | $240 | $134.7K |
| 81226 | 5 | 10 | 50 | $440 | $133.4K |
| U0004 | 2 | 20 | 360 | $70 | $116.2K |
| 86480 | 5 | 20 | 50 | $60 | $110.8K |
| 81514 | 1 | 10 | 380 | $260 | $98.7K |
Showing 1–10 of 390
Medicaid revenue breakdown by year and by CPT/HCPCS procedure code, including monthly billing trends and the top codes driving revenue.
View: By Year1 / 3
Every CPT/HCPCS code this provider has billed to Medicaid, with claims volume, average payment, and total revenue.
452 rows
| CPT/HCPCS Code | Description | Claims | Avg Paid | Revenue |
|---|---|---|---|---|
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high… | 484,790 | $60 | $29.6M |
| G0483 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but… | 230,630 | $100 | $22.4M |
| G0481 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but… | 266,850 | $50 | $12M |
| 80307 | The lab analyst performs presumptive drug test(s) via instrumented chemistry analyzers to screen for any number of drug classes on a single date. | 467,370 | $30 | $11.7M |
| 87798 | The lab analyst performs a test for an infectious agent not specified in another code using an amplified nucleic acid probe technique. Use this code if you know the laboratory technique is amplified… | 131,410 | $90 | $11.3M |
| G0482 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but… | 110,100 | $60 | $6.6M |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc,… | 371,180 | $20 | $5.9M |
| 82306 | The lab analyst measures the vitamin D level, typically on a serum specimen. This analyte, commonly known as vitamin D, is not really a vitamin, but is an important steroid hormone that is produced… | 296,110 | $20 | $4.4M |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but… | 104,130 | $40 | $3.7M |
| 87633 | The lab analyst performs a test to identify a respiratory virus using amplified nucleic acid probe technique. He may also use a multiplex reverse transcription technique. The provider does this for… | 20,870 | $140 | $3M |
Showing 1–10 of 452
How this provider's Medicaid billing volume and revenue compare to other New Jersey providers billing the same CPT/HCPCS codes.
Full comparison — all codes billed, vs. New Jersey median
452 rows
| CPT/HCPCS Code | Description | Rank | Provider Count | Median Claims | Avg Paid | Average Revenue |
|---|---|---|---|---|---|---|
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high… | 5 | 130 | 3,180 | $60 | $4.2M |
| G0483 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but… | 1 | 30 | 2,020 | $110 | $2M |
| 80050 | The lab analyst performs testing for the specific group of clinical laboratory procedures in the general health panel. Payers typically consider 80050 to apply only when the clinician orders the… | 4 | 40 | 590 | $20 | $1.9M |
| 80307 | The lab analyst performs presumptive drug test(s) via instrumented chemistry analyzers to screen for any number of drug classes on a single date. | 5 | 150 | 3,680 | $30 | $1.5M |
| G0481 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but… | 1 | 40 | 1,690 | $70 | $1.4M |
| 86480 | The lab analyst performs a test to evaluate a cell mediated immunity gamma interferon antigen response to certain tuberculosis, or TB, antibodies. | 5 | 40 | 810 | $30 | $1.4M |
| 88175 | The lab analyst performs the technical lab test to analyze a cervical or vaginal cytopathology specimen that a clinician collected in preservative fluid. The test uses automated thin layer… | 5 | 20 | 750 | $10 | $1.3M |
| 81220 | The lab analyst performs the technical lab test to detect the presence of changes in the gene for cystic fibrosis transmembrane conductance regulator, also known as CFTR. The test evaluates the CFTR… | 6 | 30 | 210 | $200 | $1.3M |
| U0004 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc, making use of high throughput technologies as described by… | 12 | 70 | 4,800 | $50 | $1M |
| 87491 | The lab analyst performs a test for Chlamydia trachomatis using amplified nucleic acid probe technique. | 5 | 120 | 900 | $20 | $971.9K |
Showing 1–10 of 452
Other providers in the same ZIP code as Accu Reference Medical Lab, LLC, ranked by combined Medicare and Medicaid revenue.
| Provider | State | Taxonomy | Medicare Revenue | Medicaid Revenue |
|---|---|---|---|---|
| Ammon Analytical Laboratories LLC | NJ | Clinical Medical Laboratory | $276.3K | $98.8M |
| Bettercare Home Health Services, LLC | NJ | Home Health Agency | $0 | $30.3M |
| Medexpress Urgent Care - Northern New Jersey, PC | NJ | Urgent Care Clinic/Center | $0 | $13.8M |
| Five Star Adult Medical Day Care Center LLC | NJ | Adult Day Care Clinic/Center | $0 | $10.8M |
| Preet Randhawa | NJ | Cardiovascular Disease Physician | $351.4K | $0 |
| David Rojer | NJ | Orthopaedic Surgery Physician | $290.4K | $0 |
| Dariusz Nowak | NJ | Endocrinology, Diabetes & Metabolism Physician | $215K | $0 |
| Julio Diaz | NJ | Internal Medicine Physician | $202.9K | $0 |
| Maria Silva-khazaei | NJ | Specialist | $176.1K | $0 |
| Paul Verona | NJ | Diagnostic Radiology Physician | $157.9K | $0 |
Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.